Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous daratumumab in high-risk smoldering multiple myeloma
CTR20182259Phase 3Suspended
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Dec 2018; status: suspended.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20182259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182259.